RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (MARKET WIRE) -- November 08, 2006 -- Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that updated clinical data from its proof-of-mechanism trial for eniluracil as well as its Phase I trial of eniluracil + 5-fluorouracil (5-FU) in solid tumors will be presented tonight by Adherex clinical investigators at the Analyst and Investor Meeting scheduled for 5-7 p.m. in New York City. The meeting will also feature presentations on Adherex’s Phase I single-agent trials of ADH-1 as well as the preclinical studies of ADH-1 in combination with chemotherapy. The Analyst and Investor Meeting will be available via live and replay webcast at www.adherex.com.
